Search

Články časopisu Gynecologic robotic surgery and our initial experience

Author of the article: R. Pilka, P. Dzvinčuk Source: Česká gynekologie | 6/2010 20. 12. 2010

News Idarucizumab reverses the anticoagulant effect of dabigatran even in patients with impaired renal function –⁠ clinical practice commentary

Along with the results of a subanalysis of the RE-VERSE AD study, which demonstrated the efficacy of idarucizumab in reversing the anticoagulant effect of dabigatran regardless of the level of renal function impairment, the October issue of the Journal of the American College of Cardiology also featured an editorial commentary by Californian cardiologists on its conclusions.

Source: Anticoagulant Treatment 10. 2. 2020

News Atectura® and Enerzair® from May 1, 2021 with Health Insurance Coverage

The fixed combination of indacaterol acetate (LABA) and mometasone furoate (ICS) Atectura® and the fixed triple combination, which in addition to these two substances also includes glycopyrronium bromide (LAMA), Enerzair® for maintenance inhalation treatment of bronchial asthma, approved in the EU last year, have established health insurance coverage in the Czech Republic from May 1, 2021. We bring a summary of the conditions for reimbursement.

Source: Asthma under control 2. 9. 2021

News Dravet Syndrome –⁠ Get to Know It

Dravet syndrome is a severe myoclonic epilepsy occurring in early childhood. It is classified as a rare progressive epileptic encephalopathy, characterized by generalized or lateralized clonic seizures often prolonged and linked to febrile infections. Other forms of seizures later appear, leading to deterioration in psychomotor development and the onset of mental retardation. Early diagnosis and treatment are desirable.

Source: Rare Diseases in Neurology 2. 5. 2023

News Dyslipidemia in the General Practitioner's Office –⁠ Featuring LDL Cholesterol

Monitoring LDL cholesterol (LDL-c) levels is crucial in diagnosing hypercholesterolemia as it is directly linked to increased cardiovascular risk. What other tests should be performed upon detecting hypercholesterolemia and which medications can effectively help reduce LDL-c levels?

Source: Hypercholesterolemia 9. 12. 2021

News Comparison of Safety and Efficacy of Oral and Intravenous Administration of Combination NEPA in the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting

Both oral and intravenous administration of a combination of netupitant (a neurokinin 1 receptor antagonist −⁠ NK1RA) with palonosetron (a 5-HT3 receptor antagonist) offer prevention of chemotherapy-induced nausea and vomiting (CINV) for up to 5 days after its administration. Although the i.v. form of netupitant (fosnetupitant) + palonosetron (NEPA) did not lead to injection site reactions or anaphylactic reactions in a Phase III study, hypersensitivity and anaphylactic reactions have been described with other i.v. administered NK1RAs. Thus, the aim of the study recently published in the journal The Oncologist was to evaluate the safety and efficacy of i.v. NEPA in women with breast cancer treated with anthracycline and cyclophosphamide-containing chemotherapy.

Source: Antiemetic Therapy 20. 1. 2020

News Quick Relief from Severe AD Symptoms –⁠ Dupilumab for Children Aged 6 Years and Older

Children aged 6-12 with severe atopic dermatitis (AD) have very limited treatment options. The studies presented below demonstrate how effective and safe dupilumab, a monoclonal antibody targeting interleukins 4 and 13, is in their case. Since October, this medication is newly covered even for children from 6 years of age.

Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 1. 11. 2021

News Increase in Hematocrit During Empagliflozin Treatment in a Diabetic Patient with Severe Anemia −⁠ A Case Study

In a case study involving a 78-year-old diabetic patient, where only the administration of empagliflozin led to the correction of severe anemia of unknown origin, Polish authors demonstrate the previously described pleiotropic effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i, i.e., gliflozins) on increasing hematocrit levels.

Source: Heart Failure 26. 7. 2022

Články časopisu The heart transplantation

Author of the article: Lenka Špinarová, Jindřich Špinar, Jiří Vítovec Source: Vnitřní lékařství | 9/2018 15. 10. 2018

News Is exposure to mite allergens in breast milk or house dust a risk factor for asthma and allergies in childhood?

Exposure to mite allergens occurs early in life from both breast milk and house dust (especially bedding). The study presented below examined the impact of exposure to the dominant mite allergen Der p 1 on serum immunoglobulin E (IgE) levels and the development of bronchial asthma in childhood.

Source: Dust Mite Allergy 23. 2. 2023

News Generic Substitution of Levothyroxine in Practice

The active ingredient levothyroxine is found in a significant number of medicinal products (MP) in the Czech Republic. The question of its generic substitution remains current, primarily because the previously published data tend to call for caution due to possible adverse effects on the patient.

Source: Thyroid Disorders 22. 2. 2024

Články časopisu Cardiorenal syndrome and gliflozins

Author of the article: Alena Šmahelová Source: Forum Diabetologicum | 3/2019 18. 12. 2019

News Position of the Aclidinium-Bromide/Formoterol-Fumarate Combination in COPD Treatment According to Current Recommendations

Dual bronchodilator therapy, which combines long-acting muscarinic antagonists (LAMA) and long-acting β-agonists (LABA), has become an integral part of the treatment for chronic obstructive pulmonary disease (COPD). Growing evidence of the efficacy and safety of the fixed combination of aclidinium-bromide/formoterol-fumarate demonstrates that this treatment meets patient needs and the current GOLD recommendations from 2019.

Source: Treatment of Asthma and COPD 3. 6. 2021

Články časopisu Promising treatment modalities in the therapy of myelodysplastic syndromes

Author of the article: A. Jonášová Source: Klinická onkologie | 5/2021 18. 10. 2021

News Genetic Testing in Clinical Practice –⁠ An Irreplaceable Tool in Prevention, Diagnosis and Treatment

Genetic testing has long ceased to be the privilege of clinical research. In practice, it is commonly used for screening, diagnosis, and prognosis determination in diseases with an evident genetic component, and subsequently for tailoring pharmacotherapy to the individual patient. The richest experience with genetic testing belongs to reproductive medicine and the field of prenatal diagnostics, as well as pediatrics associated with rare disease medicine and oncology. Today, the significance of testing is becoming apparent in internal medicine and psychiatry as well.

Source: Genetics 4. 4. 2023